WallStreetZenWallStreetZen

NASDAQ: CNTX
Context Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CNTX

Based on 4 analysts offering 12 month price targets for Context Therapeutics Inc

Min Forecast
$5.00+117.39%
Avg Forecast
$6.50+182.61%
Max Forecast
$9.00+291.3%

Should I buy or sell CNTX stock?

Based on 4 analysts offering ratings for Context Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CNTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CNTX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CNTX stock forecasts and price targets.

CNTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-22
lockedlocked$00.00+00.00%2025-11-06
lockedlocked$00.00+00.00%2025-11-06
lockedlocked$00.00+00.00%2025-09-18

1 of 1

Forecast return on equity

Is CNTX forecast to generate an efficient return?

Company
-18.96%
Industry
339.39%
Market
216.29%
CNTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CNTX forecast to generate an efficient return on assets?

Company
-17.51%
Industry
119.5%
CNTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CNTX earnings per share forecast

What is CNTX's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$0.42
Avg 2 year Forecast
-$0.41
Avg 3 year Forecast
-$0.37

CNTX revenue forecast

What is CNTX's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$7.9M

CNTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CNTX$2.30$6.50+182.61%Strong Buy
ALEC$1.93$5.00+159.07%Strong Buy
ARCT$7.33$30.83+320.64%Buy
OBIO$3.80$14.25+275.00%Strong Buy
VYGR$3.74$16.50+341.18%Buy
View Top Biotech Stocks

Context Therapeutics Stock Forecast FAQ

Is Context Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CNTX) stock is to Strong Buy CNTX stock.

Out of 4 analysts, 3 (75%) are recommending CNTX as a Strong Buy, 1 (25%) are recommending CNTX as a Buy, 0 (0%) are recommending CNTX as a Hold, 0 (0%) are recommending CNTX as a Sell, and 0 (0%) are recommending CNTX as a Strong Sell.

If you're new to stock investing, here's how to buy Context Therapeutics stock.

What is CNTX's earnings growth forecast for 2026-2028?

(NASDAQ: CNTX) Context Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.

Context Therapeutics's earnings in 2026 is -$26,440,916.On average, 11 Wall Street analysts forecast CNTX's earnings for 2026 to be -$38,478,999, with the lowest CNTX earnings forecast at -$58,076,828, and the highest CNTX earnings forecast at -$20,259,359. On average, 11 Wall Street analysts forecast CNTX's earnings for 2027 to be -$37,486,704, with the lowest CNTX earnings forecast at -$45,020,797, and the highest CNTX earnings forecast at -$24,118,284.

In 2028, CNTX is forecast to generate -$33,738,034 in earnings, with the lowest earnings forecast at -$59,427,452 and the highest earnings forecast at -$964,731.

What is CNTX's revenue growth forecast for 2026-2028?

(NASDAQ: CNTX) Context Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.

Context Therapeutics's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast CNTX's revenue for 2026 to be $0, with the lowest CNTX revenue forecast at $0, and the highest CNTX revenue forecast at $0. On average, 10 Wall Street analysts forecast CNTX's revenue for 2027 to be $0, with the lowest CNTX revenue forecast at $0, and the highest CNTX revenue forecast at $0.

In 2028, CNTX is forecast to generate $723,456,640 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,522,923,284.

What is CNTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CNTX) forecast ROA is -17.51%, which is lower than the forecast US Biotechnology industry average of 119.5%.

What is CNTX's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CNTX price target, the average CNTX price target is $6.50, with the highest CNTX stock price forecast at $9.00 and the lowest CNTX stock price forecast at $5.00.

On average, Wall Street analysts predict that Context Therapeutics's share price could reach $6.50 by Dec 22, 2026. The average Context Therapeutics stock price prediction forecasts a potential upside of 182.61% from the current CNTX share price of $2.30.

What is CNTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CNTX) Context Therapeutics's current Earnings Per Share (EPS) is -$0.24. On average, analysts forecast that CNTX's EPS will be -$0.42 for 2026, with the lowest EPS forecast at -$0.63, and the highest EPS forecast at -$0.22. On average, analysts forecast that CNTX's EPS will be -$0.41 for 2027, with the lowest EPS forecast at -$0.49, and the highest EPS forecast at -$0.26. In 2028, CNTX's EPS is forecast to hit -$0.37 (min: -$0.65, max: -$0.01).

What is CNTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CNTX) forecast ROE is -18.96%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.